- Home
- CLLS vs FBRX Comparison
CLLS vs FBRX Comparison
Compare CLLS & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | FBRX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 379.3M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLLS | FBRX |
|---|---|---|
| Price | $3.24 | $26.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.50 | ★ $67.00 |
| AVG Volume (30 Days) | 48.3K | ★ 185.6K |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $4.91 |
| 52 Week High | $5.48 | $35.62 |
Technical Indicators
Market Signals| Indicator | CLLS | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 47.03 |
| Support Level | $3.32 | $26.67 |
| Resistance Level | $3.83 | $32.40 |
| Average True Range (ATR) | 0.21 | 2.25 |
| MACD | -0.02 | -0.18 |
| Stochastic Oscillator | 22.37 | 50.87 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).